✦ LIBER ✦

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

✍ Scribed by Fabio P. S. Santos; Hagop Kantarjian; Carmen Fava; Susan O’Brien; Guillermo Garcia-Manero; Farhad Ravandi; William Wierda; Deborah Thomas; Jianquin Shan; Jorge Cortes

Book ID: 108676836
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 202 KB
Volume: 150
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2010.08245.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety profiles of second-line tyrosine

Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

✍ Sara M Tinsley 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Second-Generation Tyrosine Kinase Inhibi

Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)

✍ Abruzzese, Elisabetta; Breccia, Massimo; Latagliata, Roberto 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 451 KB

Erratum to: Second-Generation Tyrosine K

Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)

✍ Abruzzese, Elisabetta; Breccia, Massimo; Latagliata, Roberto 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 125 KB

Clinical efficacy of second generation t

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis

✍ Ghez, David; Micol, Jean-Baptiste; Pasquier, Florence; Auger, Nathalie; Saada, V 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 292 KB

A Comparison of Methodologies for Estima

A Comparison of Methodologies for Estimating Survival in Patients Treated with Second-generation Tyrosine-kinase Inhibitors (TKIs) for Chronic Myeloid Leukaemia (CML)

✍ Pennington, B.; Batty, A.J.; Clifton-Brown, E. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Front-Line Therapy With Second-Generatio

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

✍ Jabbour, E.; Kantarjian, H. M.; O'Brien, S.; Shan, J.; Quintas-Cardama, A.; Garc 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 126 KB